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Abstract
Background: Gene transfer to the gastrointestinal (GI) mucosa is a therapeutic strategy which could prove particularly 
advantageous for treatment of various hereditary and acquired intestinal disorders, including inflammatory bowel 
disease (IBD), GI infections, and cancer.
Methods: We evaluated vesicular stomatitis virus glycoprotein envelope (VSV-G)-pseudotyped lentiviral vectors (LV) 
for efficacy of gene transfer to both murine rectosigmoid colon in vivo and human colon explants ex vivo. LV encoding 
beta-galactosidase (LV-β-Gal) or firefly-luciferase (LV-fLuc) reporter genes were administered by intrarectal instillation in 
mice, or applied topically for ex vivo transduction of human colorectal explant tissues from normal individuals. 
Macroscopic and histological evaluations were performed to assess any tissue damage or inflammation. Transduction 
efficiency and systemic biodistribution were evaluated by real-time quantitative PCR. LV-fLuc expression was evaluated 
by ex vivo bioluminescence imaging. LV-β-Gal expression and identity of transduced cell types were examined by 
histochemical and immunofluorescence staining.
Results: Imaging studies showed positive fLuc signals in murine distal colon; β-Gal-positive cells were found in both 
murine and human intestinal tissue. In the murine model, β-Gal-positive epithelial and lamina propria cells were found 
to express cytokeratin, CD45, and CD4. LV-transduced β-Gal-positive cells were also seen in human colorectal explants, 
consisting mainly of CD45, CD4, and CD11c-positive cells confined to the LP.
Conclusions: We have demonstrated the feasibility of LV-mediated gene transfer into colonic mucosa. We also 
identified differential patterns of mucosal gene transfer dependent on whether murine or human tissue was used. 
Within the limitations of the study, the LV did not appear to induce mucosal damage and were not distributed beyond 
the distal colon.
Background
Gene transfer to the gastrointestinal (GI) mucosa is a
therapeutic strategy which could prove particularly
advantageous for treatment of various hereditary and
acquired intestinal disorders, including inflammatory
bowel disease (IBD), GI infections, and cancer [1-5].
Non-viral vectors for delivery of exogenous DNA are
limited by low efficiency of transduction in vivo, and do
not provide long-term expression [6]. First-generation
retroviral vectors can achieve long-term expression
through their ability to integrate permanently in the
genome of target cells, but gene transfer to the GI tract by
these vectors was also found to be inefficient [7-10]. Con-
versely, adenoviral vectors can infect a wide range of cells,
including intestinal epithelial cells, and show high levels
of transgene expression [11,12], but these are non-inte-
grating vectors and so expression is transient [13]. Fur-
thermore, adenoviral vectors induce robust cellular and
humoral immune responses in vivo, resulting in elimina-
tion of transduced cells and neutralization of the vector
upon repeat administration [14]. In contrast, adeno-asso-
ciated virus (AAV) vectors lack all viral genes and have
limited capacity to induce cell mediated immune
responses. In addition, AAV may have the potential to
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transduce intestinal crypt progenitor cells resulting in
extended transgene expression [15].
LV, such as those derived from human immunodefi-
ciency virus (HIV), are distinct from earlier generation
retroviral vectors in their ability to infect quiescent cells
through active import of the viral preintegration complex
across the intact nuclear membrane, even in post-mitotic
cells [16,17]. LV pseudotyped with the vesicular stomati-
tis virus envelope glycoprotein (VSV-G) exhibit an
e x p a n d e d  h o s t  r a n g e  t h a t  a l l o w s  e n t r y  i n t o  m o s t  c e l l
types in a wide variety of species ranging from zebrafish
to man [18]. Highly efficient gene delivery by VSV-G-
pseudotyped LV has been reported in various types of
terminally differentiated primary cells in vitro and in vivo,
including neurons, hepatocytes, cardiomyocytes, vascu-
lar endothelium, alveolar pneumocytes, and keratino-
cytes [19-29]. With regard to intestinal cells, these vectors
have been shown to be capable of transducing human and
canine colonic epithelial cell lines via the apical mem-
brane in polarized monolayer cultures in vitro [30]. How-
ever, to date there have been no studies evaluating VSV-
G-pseudotyped LV for gene delivery to primary intestinal
cells, especially those subjacent to the mucosal epithelia,
particularly in the context of the architecturally complex
native tissue.
Therefore, in these studies we tested the ability of VSV-
G-pseudotyped LV to deliver reporter genes to colonic
mucosa via the apical surface in vivo, after intraluminal
instillation per rectum in a murine model, and ex vivo in a
human intestinal explant system [31].
Methods
Vector construction
The pRRLsin-hCMV-β-Gal vector was constructed by
insertion of the β-Gal reporter gene from plasmid pSV-β-
Gal (Promega, Madison, WI, USA), and the pRRLsin-
hCMV-fLuc vector was constructed by insertion of the
fLuc gene [32], respectively, into the multiple cloning site
(MCS) of pRRLsin-hCMV-MCS-pre, a third-generation,
self-inactivating LV construct kindly provided by Dr.
Luigi Naldini (University of Milan, Italy) [33] (Figure 1A).
Cell culture, virus production, and in vitro gene transfer
Human embryonic kidney cell line 293T, and human
colon cancer cell lines Caco-2, LoVo, and WiDr, (ATCC,
Manassas, VA, USA), were cultured in Dulbecco's modi-
fied Eagle's medium (DMEM), Ham's F12K, or RPMI-
1640 medium, respectively, with 10% fetal bovine serum
and 1% penicillin-streptomycin. LV virus was produced
in 293T cells using a third-generation packaging system
as previously described [34], using either pRRLsin-
hCMV-β-Gal or pRRLsin-hCMV-fLuc, to produce LV-β-
Gal or LV-fLuc, respectively. Virus titers were determined
by HIV-1 p24 ELISA (Perkin Elmer, Waltham, MA, USA)
and expressed as p24 equivalent units (ng/ml). Vector
transductions were performed on 1 × 105 target cells with
8 μg/mL polybrene (Sigma, St. Louis, MO, USA) at 37°C.
Polybrene is a small, positively charged molecule that
binds to cell surfaces and neutralizes surface charge and
has been shown to enhance cell transduction by retrovi-
ruses [35].
After replacement of the medium and further incuba-
tion for 24 hr, cells were washed twice in phosphate-buff-
ered saline (PBS), fixed in 2% formaldehyde/0.2%
glutaraldehyde (Sigma, St. Louis, MO) for 10 min at room
temperature, and stained with 20 mg/ml X-Gal solution
(5-bromo-4-chloro-3-indolyl beta-D-galactoside; Sigma,
St. Louis, MO, USA) at 37°C for 2 hr.
In vivo studies
All in vivo studies were performed according to institu-
tional guidelines under protocols approved by the UCLA
Animal Research Committee. Briefly, 6 to 8-week-old
f e m a l e  B A L B / c  m i c e  ( C h a r l e s  R i v e r  L a b o r a t o r i e s  I n c . ,
Wilmington, MA, USA) were divided into a non-treated
control (NC) group, and two groups that received
intrarectal instillation of either LV or vehicle solution
(DMEM). Prior to instillation, anesthetized mice were
given an intrarectal enema of 50% ethanol (vol/vol in dis-
tilled H2O). Pretreatment with ethanol enemas has been
shown to increase intestinal transduction with other vec-
tors [36]. Two hours after the enema, 100 μL of vehicle or
viral vector solution containing a total of approximately
1000 ng p24 equivalent units was instilled intrarectally.
The mice were inverted for 30 sec after administration of
intrarectal products to prevent leakage.
Macroscopic assessment and ex vivo bioluminescence 
imaging
Health status and body weight was monitored through-
out the study. On days 2, 7, and 21 after vector or vehicle
instillation, cohorts of mice were sacrificed, and the
Figure 1 Lentiviral vector (LV) constructs and ex vivo explant cul-
ture system. (A) Schematic representation of self-inactivating vectors 
containing a central polypurine tract (cPPT)/central termination se-
quence, immediate early cytomegalovirus (CMV) promoter. Vectors 
were constructed for expression of beta-galactosidase (β-Gal) and fire-
fly luciferase (fLuc).Matsumoto et al. BMC Gastroenterology 2010, 10:44
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entire colon was removed. Colon length from cecum to
anus, weight, and a macroscopic colonic damage score
were recorded The macroscopic colonic damage score
was based on the degree of tissue adhesion, mucosal
ulceration, and intestinal wall thickness (Table 1) [37].
Ex vivo bioluminescence imaging was performed 2 days
after rectal instillation of LV-fLuc using the Xenogen IVIS
system (Caliper Life Sciences, Alameda, CA, USA). Bio-
luminescent signal intensity was expressed as photons
per second per cm2 per steridian (p/s/cm2/sr), and color
i m a g e s  w e r e  p r o c e s s e d  w i t h  L i v i n g  I m a g e  a n d  I G O R -
PRO analysis software (Wave Metrics, Portland, OR,
USA).
Histological evaluation and X-Gal histochemical staining
For routine histology, colon and other tissues (spleen,
liver, lung, kidney) were fixed in 4% paraformaldehyde
overnight, placed in 30% sucrose/PBS for 2 hr, and
embedded in OCT compound. Serial 5-μm cryosections
were stained with hematoxylin/eosin (H&E) for evalua-
tion of histopathology score. Mucosal inflammation was
scored using a semi quantitative technique (Table 2) [38].
For X-Gal histochemistry, tissues were fixed in 2% glu-
taraldehyde for 2 hr, embedded in OCT compound, and
10-μm cryosections were stained in 1 mg/ml X-Gal solu-
tion at 37°C for 24sr, rehydrated, and counterstained with
0.1% Nuclear Fast Red (Sigma, St. Louis, MO, USA). The
number of positive staining cells was counted in five
independent fields in random areas on two non-consecu-
tive slides at 200× magnification.
Real-time quantitative PCR (qPCR) analysis
Quantification of vector copy number was performed at
e a c h  t i m e  po i n t  b y  T a q M a n  q PCR  as s a y  t o  d e t ect  t h e
HIV-1 packaging signal sequence, using 300 ng genomic
DNA (equivalent to 5 × 104  genomes) isolated from
murine colon and other tissues, including stomach, small
intestine, liver, kidney, spleen, lung, heart, brain, and
bone marrow [39]. A reference curve was prepared by
amplifying serial dilutions of LV-encoding plasmid in a
background of genomic DNA isolated from untrans-
duced murine colon. Genomic DNA from a PC3 cell line
previously confirmed by flow cytometry to be 100%
transduced by LV-GFP vector was used as a positive assay
control.
Human colorectal tissue explant culture and ex vivo gene 
transfer
All human endoscopic biopsies were collected from
healthy HIV-negative volunteers at UCLA Medical Cen-
ter, Los Angeles, USA. The protocol for the use of human
endoscopic biopsies was approved by Institutional
Review Board of the David Geffen School of Medicine at
UCLA (#02-05-001-13).
Explant cultures were established as previously
described [31]. Briefly, explants were placed on presoaked
Gelfoam® (Pharmacia and Upjohn Company, Kalamazoo,
MI, USA) rafts with the epithelium uppermost. Tissues
were transduced by pipetting LV solution and polybrene
(8 μg/mL) onto the top of each Gelfoam®-supported
explant. After 2 hr incubation, tissues were washed three
times, placed on fresh Gelfoam ® rafts, and incubated at
Table 2: Histological Scoring System
Infiltration of inflammatory cells
Score Observation
0 Rare inflammatory cells in the lamina propria
1 Increased numbers of inflammatory cells in the 
lamina propria
2 Confluence of inflammatory cells extending into the 
submucosa
3 Transmucosal infiltrates
Tissue Damage
Score Observation
0N o  m u c o s a l  d a m a g e
1 A discrete lymphoepithelial lesion
2S u r f a c e  m u c o s a l  e r o s i o n
3 Extensive mucosal damage and ulceration
Table 1: Macroscopic Colonic Damage Score System
Tissue Adhesion
Score Observation
0 No adhesion
1 Little effort required to separate the colon from the 
surrounding tissue
2 Moderate effort required to separate the colon from 
the surrounding tissue
3 Severe adhesions
Degree of ulceration
Score Observation
0 Normal appearance of the colon
1 Focal hyperemia with no ulcer
2 Presence of an ulcer and inflammation
3 Two (2) or more ulcers and regions of inflammation
Wall thickness
Score Observation
0N o r m a l  t h i c k n e s s
1 Mild thickening
2 Moderate thickening
3 Severe bowel thickeningMatsumoto et al. BMC Gastroenterology 2010, 10:44
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37°C for a total of 24 hr. Explants were then either fixed in
glutaraldehyde, embedded in OCT, and 10-μm cryosec-
tions prepared for X-Gal as above, or were fixed in form-
aldehyde, embedded in OCT, and 7-μm sections
prepared for immunofluorescence staining.
Immunofluorescence staining and quantitative 
morphometry
The identity of transgene-expressing cells in harvested
murine colon tissues or human colorectal explant tissues
was examined by immunofluorescence double-staining
with antibodies against β-Gal and cell-specific pheno-
typic markers. Briefly, serial 7-μm cryosections were
stained for E. coli β-Gal (Promega, Madison, WI, USA).
Additional staining included antibodies directed against
human and murine cytokeratin AE1/AE3 and CD45
(Dako North America Inc., Carpinteria, CA, USA); and
CD4, CD8, and CD11c (BD Pharmingen, Franklin Lakes,
NJ, USA). β-Gal staining was then visualized with Alexa
Fluor® 594. Cytokeratin and CD45 were visualized with
Alexa Fluor® 488 (Invitrogen Corporation, Carlsbad, CA,
USA). The CD4, CD8, and CD11c antibodies were
already conjugated with Alexa Fluor 488. The Vector
mouse-on-mouse (M.O.M™) Immunodetection Kit (Vec-
tor Laboratories, Burlingame, CA, USA) was used to
avoid the high background staining caused by antibody
binding to endogenous murine immunoglobulin when
secondary antibodies were used to amplify primary
murine antibodies. Slides were mounted and nuclei coun-
terstained using VECTASHIELD® and DAPI (4',6-diamid-
ino-2-phenylindole; Vector Laboratories, Burlingame,
CA, USA). In order to quantify LV-mediated β-Gal trans-
duction efficiency, the total number of cells showing co-
localization of β-Gal-positive and CD45 or CD4 positive
signals in 3 randomly selected fields per section at 200 ×
magnification were identified, and expressed as percent-
ages of the total number of β-Gal-positive cells or the
total number of CD45 +/CD4+ cells.
Statistical analysis
All values were expressed as means ± SD. Comparisons
between groups were made using the Student t-test and
the Mann-Whitney U test, and p values <0.05 were con-
sidered statistically significant.
Results
LV-mediated gene transfer to human colorectal cancer cell 
lines in vitro
LV-mediated transduction efficiency was first assessed in
vitro using human colorectal adenocarcinoma cell lines
Caco-2, WiDr, and LoVo. In each cell line, a dose-depen-
dent increase in the number of cells showing positive sig-
nals upon X-Gal staining was observed with increasing
LV concentration (Figure 2A, B). The highest dose tested
was 10 ng p24 equivalent units of LV, which corresponds
to a biological infectious titer of 106 transducing units
(TU) on a standardized cell line such as 293T [40]. At this
dose, transduction rates per 1 × 105 target cells were
40.6% for WiDr, 13.7% for Caco-2, and 13.3% for LoVo,
indicating that although these colon adenocarcinoma cell
lines are less permissive for LV compared to 293T embry-
onic kidney cells, significant gene transfer can be
achieved with higher multiplicities of infection. Seppen et
al. have previously reported higher rates of transduction
in Caco-2 cells but used a transwell system with GFP
expressing first and third generation lentiviral vectors
[41].
Administration of LV for transduction of murine colorectal 
mucosa in vivo
The safety of gene transfer procedures using LV express-
ing either fLuc or β-Gal was assessed by both macro-
scopic and histopathologic criteria in three experimental
groups; mice receiving the LV, mice receiving a mock
installation (the viral plasmid solution in DMEM), and a
control group (N = 8 per condition) Intrarectal adminis-
tration of 1000 ng p24 equivalent units of VSV-G-
pseudotyped LV, corresponding to a 293T cell-based
standardized biological titer of 108 TU, did not affect
body weight or induce any gross abnormalities upon rou-
tine observation. The ratio of colon weight-to-length was
0.33 ± 0.04 in the non-treated control (NC) group, 0.34 ±
0.5 in the mock instillation control group, and 0.27 ± 0.4
in the LV instillation group. Thus, there were no signifi-
Figure 2 In vitro transduction of vesicular stomatitis virus G pro-
tein (VSV-G)-pseudotyped lentivirus (LV) encoding β-Gal in co-
lonic cell lines. (A) Percentage of cells transduced by the VSV-G-
pseudotyped LV. One hundred cells were counted in three randomly 
selected, non-adjacent fields in triplicate. (B) Colon adenocarcinoma 
cell lines showing evidence of β-Gal transduction following exposure 
to 10 ng p24 of vector. All values were expressed as means ± SD. *p < 
0.05 compared with the results of 0.1 ng p24 VSV-G LV transduction.Matsumoto et al. BMC Gastroenterology 2010, 10:44
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cant differences among these three groups in macro-
scopic damage assessment or histopathological
evaluation scores (Additional File 1). More specifically,
the use of ethanol enemas did not appear to induce signif-
icant mucosal damage. No pathological findings could be
observed in kidney, spleen, lung, and liver harvested from
control and LV-treated mice at each time point (data not
shown).
Ex vivo bioluminescence murine imaging following rectal 
instillation of LV-fLuc
Strong positive signals were observed in the distal colon
adjacent to the rectum in 8/8 (100%) of mice exposed to
VSV-G-pseudotyped LV encoding the fLuc reporter gene
(Figure 3A). Quantitative measurement of biolumines-
cent photon emission from LV-transduced distal colon
showed a significantly higher level of transduction than
that of mock-treated colon (57560 ± 28960 p/s/cm2/sr for
the LV instillation group vs. 6260 ± 813.3 p/s/cm2/sr for
the mock instillation group; p < 0.001) (Figure 3B). Addi-
tional studies are needed to determine whether the physi-
cal distribution of the ethanol enemas and/or the LV
influenced the location of the bioluminescence signal.
Figure 3 Bioluminescence imaging analysis. (A) Ex vivo bioluminescence imaging analysis after rectal administration of vesicular stomatitis virus-G 
protein (VSV-G)-pseudotyped lentivirus (LV) expressing firefly-luciferase (fLuc). This pseudocolor image, which is superimposed on a grayscale refer-
ence image, uses color (blue, least intense; red, most intense) to illustrate signal strength. (B) Photon emission (p/s/cm2/sr) in the region of interest 
(ROI) of colon transduced by VSVG-pseudotyped LV shows significantly higher levels of transduction compared to the mock control. (C) Biodistribu-
tion of VSV-G LV after rectal administration demonstrated by real-time quantitative polymerase chain reaction (qPCR) analysis of viral copy number in 
300 ng of genomic DNA of in vivo (equivalent to approximately 50,000 cells). The detection limit was 50 copies per 300 ng genomic DNA.Matsumoto et al. BMC Gastroenterology 2010, 10:44
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Real-time qPCR analysis of LV transduction in murine colon 
tissue
Real-time qPCR was employed to quantify the vector
copy number of LV integrated into genomic DNA from
murine colon tissues after in vivo administration. Using
spiked samples to obtain a reference curve, this method
was determined to be sensitive enough to detect 50 cop-
ies of LV per 5 × 104 cellular genomes. Genomic DNA
from both positive control cells (data not shown) and
transduced rectosigmoid colon showed amplification of
proviral LV sequences. The average copy number per 300
ng genomic DNA from LV-transduced colon was 231.3 ±
183.7 (Figure 3C). As expected, no detectable qPCR sig-
nals were observed in genomic DNA from colon tissues
of non-treated or mock-treated controls. Importantly,
even in LV-treated animals at 2 days post-vector instilla-
tion, no detectable qPCR signals were found in any extra-
intestinal tissues examined, including stomach, small
intestine, liver, kidney, spleen, lung, heart, brain, and
bone marrow (Figure 3C). As the LV was not treated with
DNAse prior to injection, we cannot exclude the possibil-
ity that the data in Fig 3C in part reflect plasmid contami-
nation.
X-Gal histochemistry and double immunofluorescence 
staining of LV-βGal transduction in murine colon tissues
Histochemistry was performed using optimized X-Gal
concentrations and pH conditions to minimize back-
ground staining due to endogenous mammalian β-galac-
tosidase in the GI tract. As expected, under these
conditions, no staining was observed in mouse colon tis-
sues from non-treated and mock-treated control groups,
nor in the non-intestinal tissues (kidney, spleen, lung, and
liver) from any animals including the LV-treated group.
In contrast, positive-staining cells were observed in
colon tissues from animals treated with LV expressing the
E. coli β-Gal reporter gene. The initial number of posi-
tive-staining cells in the LV-treated group was 62.3 ± 18.5
per microscopic field at 200× magnification on Day 2
post-vector instillation (Figure 4). However, the number
of positive-staining cells was then observed to decrease,
to 19.1 ± 5.3 per 200 × field on Day 7, and 15.7 ± 5.1 per
200 × field on Day 21. These positive-staining cells were
found predominantly toward the luminal surface of the
c o l o n ,  b u t  w e r e  i d e n t i f i e d  i n  b o t h  m u c o s a l  e p i t h e l i u m
and, importantly, the lamina propria (LP) (Figure 5A).
To further characterize the identity of the transduced
cells, immunofluorescence double-staining was per-
formed using an E. coli β-Gal-specific antibody in combi-
nation with various cellular immunophenotypic
antibodies. Quantification of double-positive staining in
colon tissues harvested on Day 2 post-LV instillation
demonstrated that 27 ± 5% of the β-Gal-positive cells
were also positive for cytokeratin. Consistent with their
histological origin, β-Gal/cytokeratin double-positive
cells were observed solely in the epithelial layers of colon
tissues from transduced animals. Cells exhibiting double-
positive staining for both β-Gal and the common leuko-
cyte antigen CD45 were found in both mucosal epithe-
lium and lamina propria (LP) regions. These β-Gal/CD45
double-positive cells represented 70 ± 11% of the total
population of β-Gal-positive cells.
A subset of LV-transduced white blood cells was fur-
ther identified to consist of T lymphocytes, dendritic
cells, or macrophages, as 27 ± 2% of the total population
of β-Gal-positive cells were also positive for CD4. In fact,
of the total population of CD4-positive cells, 48 ± 13%
were β-Gal-positive, indicating a significant transduction
of half of this cell population. These β-Gal/CD4 double-
positive cells were observed only within the LP of trans-
duced murine colon. Notably, there were no cells showing
co-expression of both β-Gal and CD8 or CD11c (Figure
5B-F).
LV-β Gal-mediated ex vivo gene transfer to human 
colorectal explant tissues
Human colon tissue specimens were incubated with 1000
ng p24 units of LV-β-Gal, and examined within 24 hr of
explant culture. The number of X-Gal-positive cells after
transduction was 12.4 ± 1.5 per low power (×200) field. In
contrast to the murine studies, the transduced cells in
human samples were primarily found within the LP (Fig-
ure 6A). These data might reflect the availability of both
Figure 4 X-Gal histology in murine colon transduced by vesicular 
stomatitis virus G protein (VSV-G)-pseudotyped lentivirus (LV) 
encoding β-Gal in vivo. The time course of β-Gal expression in the co-
lon of BALB/c mice. Each group had 6 mice. The colon was removed at 
the indicated time points. The number of X-Gal-positive cells in murine 
colon transduced by LV-β-Gal in vivo. All values were expressed as 
means ± SD. *p < 0.05 compared with the results of normal control 
(NC).Matsumoto et al. BMC Gastroenterology 2010, 10:44
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apical and basal aspects of the explant to LV transduc-
tion, and/or the use of polybrene. By double immunofluo-
rescence staining using human cellular
immunophenotypic antibodies, 84 ± 16% of β-Gal-posi-
t i v e  c e l l s  w e r e  a l s o  f o u n d  t o  be  pos i t i v e  f o r  CD 4 5 .  O f
these, 41 ± 12% of β-Gal-positive cells were found to be
CD4-positive, and 35 ± 8% were CD11c-positive. Nota-
bly, no β-Gal-positive cells expressed CD8 or cytokeratin
(Figure 6B-F). Non-specific background staining was not
observed using this technique (Additional File 2). This
identifies transduced cells as mucosal lamina propria
CD4+ lymphocytes, macrophages, dendritic cells, and
other leukocytes. Consistent with the results obtained
after in vivo LV instillation in mice, 54 ± 15% of the total
population of CD4-positive cells in ex vivo LV-transduced
human explant tissues were also positive for β-Gal. We
did not perform immunohistochemical examination of
mesenteric lymph node tissue and so we do not know
whether L V transduced cells could be identified at this
site.
Discussion
Using a combination of molecular, imaging, and histolog-
ical techniques, we have demonstrated for the first time
that VSV-G-pseudotyped LV can mediate detectable
gene transfer to architecturally intact human and murine
intestinal mucosa after topical application. The overall
transduction level was observed to decrease over time,
with a 3-fold reduction between Day 2 and Day 7, but was
then relatively consistent between Day 7 and Day 21. This
may reflect both initial transgene expression from uninte-
grated episomal reverse-transcribed circular forms of LV
provirus, which is transient in duration, as well as
reduced numbers of transduced non-adherent cells (such
Figure 5 Double immunofluorescence histology analysis in murine colon. (A) Histochemical analysis of transduced murine colon in vivo. The X-
Gal-positive cells were evident mainly on the luminal surface of the distal colon (magnification × 400). (B-F) Double immunofluorescence staining of 
tranduced murine colon examined under confocal microscopy. On Day 2 following rectal administration, β-Gal-positive cells in murine colon tissue 
expressed CD45, CD4, and cytokeratin, but not CD8 or CD11c. In these photomicrographs, β-Gal-positive cells are visualized by red fluorescence, CD 
phenotypes and cytokeratin are visualized by green fluorescence, and all images display fluorescence overlays: (B) β-Gal and CD45; (C) β-Gal and CD4; 
(D) β-Gal and CD8; (E) β-Gal and CD11c; and, (F) β-Gal and cytokeratin. Double-positive cells indicated by the arrowheads are yellow. (EP; epithelial 
cell, LP; lamina propria cell)Matsumoto et al. BMC Gastroenterology 2010, 10:44
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as lymphocytes) as they migrate or circulate out of colon
tissue in vivo, or reflect cells lost through apoptosis or
karyolysis in the ex vivo explant model.
An additional finding is the demonstration that in
human intestinal tissue, the transduced cells are predom-
inantly in the lamina propria, an observation differing
from previous beliefs that it is predominantly epithelial
lineage cells that are transduced. Co-localization of phe-
notypic cell surface markers and transgene expression
showed notable differences in the types of cells trans-
duced between experiments involving LV-mediated
transduction of murine vs. human colon tissue. Signifi-
cant transduction of cytokeratin-positive cells was
observed after in vivo transduction of murine colon, but
not after ex vivo transduction of human explants colon
tissue. Conversely, after ex vivo transduction of human
explant colon tissue, but not after in vivo transduction of
murine colon, we observed significant transduction of
cells positive for CD11c, a cellular marker of mac-
rophages and dendritic cells, but which is also weakly
expressed on B cells, NK cells, and T cell subsets.
A number of parameters may have contributed to these
differences. For example, to avoid degradation of the tis-
sue architecture, LV-transduced human colon tissues had
to be analyzed after no more than 24 hours of explant cul-
ture, and the time course for accumulating a detectable
level transgene product may require a longer time inter-
val for epithelial cells. Of course, LV transduction after
rectal instillation in vivo also necessitates penetration
from the intestinal lumen, and the mucosal epithelium
represents the only tissue surface directly in contact with
the virus solution. In contrast, virus applied ex vivo to the
surface of endoscopically acquired human tissue explant
samples has access to sub-epithelial cell layers that would
not normally be available to virus administered intralu-
minally to intact intestine in vivo. Another difference
between the in vivo and ex vivo experiments was the use
of ethanol in the former, and polybrene in the latter, to
Figure 6 X-Gal histology and double immunofluorescence histology analysis in human colonic explants transduced by VSV-G-pseudo-
typed lentivirus (LV) encoding β-Gal. (A) Histological appearance of transduced human explants after X-Gal staining. X-Gal-positive cells, here 
stained blue, were found mainly in the LP. (B-F) Double immunofluorescence confocal microscopy of human explants transduced with VSV-G. β-Gal-
positive cells expressed CD4, CD45, and CD11c, but not CD8, or cytokeratin. In these photomicrographs, β-Gal is visualized by red fluorescence, each 
cellular phenotype marker is visualized by green fluorescence, and nuclei are visualized by blue DAPI staining, respectively, and all images display flu-
orescence overlays: (B) β-Gal and CD45; (C) β-Gal and CD4; (D) β-Gal and CD8; (E) β-Gal and CD11c; and, (F) β-Gal and cytokeratin. Double-positive 
cells, indicated by the arrowheads, are yellow (EP; epithelial cell, LP; lamina propria cell).Matsumoto et al. BMC Gastroenterology 2010, 10:44
http://www.biomedcentral.com/1471-230X/10/44
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facilitate lentiviral transduction. We did not explore the
extent to which these different experimental parameters
might influence the results of our experiments.
We did observe a difference between the present study
and previous studies using explant tissues, in terms of the
specific localization of transduced cells within the LP. In
the present study, LV-transduced cells in human explant
samples were found primarily in the subepithelial region
of the LP whereas in other colorectal explant studies
using adenoviral vectors [42] transduction was com-
monly observed in the basolateral region. However, it is
difficult to compare our data with other published studies
as the cell tropism may differ between vectors. In addi-
tion, differences in the histological distribution of vector-
specific cellular receptors, such as the coxsackievirus/
adenovirus receptor (CAR) required for efficient binding
of adenovirus to target cells may influence experimental
results.
There were also similarities in cell transduction results
from the murine rectal in vivo transduction and human
explant ex vivo transduction models. In both cases, VSV-
G-pseudotyped LV exhibited the ability to transduce
CD4-positive cell population. Notably, LV pseudotyped
with the VSV-G envelope, which only requires binding to
phospholipid constituents of most mammalian cells [43],
achieved much more efficient infection of T cells than is
possible with identical vectors pseudotyped with ampho-
tropic retrovirus envelope [44]. However, CD4 is not only
expressed by helper T lymphocytes and T regulatory
cells, but also by macrophages and dendritic cells at lower
levels. All of these cell types generally reside in the LP,
which is where the predominant staining was observed in
humans. It is not clear why the LV was unable to trans-
duce CD8 positive cells and this finding warrants addi-
tional in vitro studies with purified T cell populations.
As the vectors used are replication-defective and can
only mediate a single cycle of infection, this finding sug-
gests that LV may be efficiently transported intact across
the mucosal epithelium as has been suggested as a natural
route of HIV infection. It has also been reported that den-
dritic cells may form projections into the intestinal lumen
to sample incoming antigens, which may permit HIV
infection as well as LV transduction of this cell popula-
tion.
Conclusions
In summary, these studies have demonstrated the feasi-
bility of using VSV-G-pseudotyped LV to safely achieve
appreciable levels of localized gene transfer into architec-
turally intact primary murine and human intestinal tis-
sues.
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